ACE Inhibitors vs. ARBs in Hypertension with CKD

Mechanisms of Action

ACE Inhibitors (e.g., lisinopril, enalapril):

• Block angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II
• Reduce breakdown of bradykinin (leading to cough side effect)
• Decrease aldosterone secretion → reduced sodium/water retention

ARBs (e.g., losartan, valsartan):

• Directly block angiotensin II type 1 receptors (AT1 receptors)
• Allow angiotensin II to bind to AT2 receptors (which may have protective effects)
• Do not affect bradykinin metabolism (thus no cough)

Key Clinical Differences in CKD Patients

1. Renoprotection: Both classes reduce intraglomerular pressure and proteinuria via vasodilation of efferent arterioles
2. Cough: ACE inhibitors cause dry cough in 5-20% (bradykinin-mediated); ARBs don't
3. Angioedema: Rare but serious with ACE inhibitors; much less with ARBs
4. Potassium retention: Similar risk with both classes in CKD patients
5. Cost: ACE inhibitors are generally less expensive

Clinical Guidelines for Selection

KDIGO 2021 Guidelines recommend:

• First-line: ACEi or ARB for hypertension in CKD with proteinuria (>300 mg/day)
• Choice considerations:
  • Use ACEi unless contraindicated (often due to cost)
  • Switch to ARB if ACEi causes cough or angioedema
  • Avoid combined ACEi+ARB therapy (increased adverse events without added benefit)
  • Monitor serum creatinine and potassium within 2-4 weeks after initiation/uptitration

Special CKD Considerations:

• Volume status: Ensure euvolemia before initiation (prevents acute kidney injury)
• Staging-based approach:
  • CKD G1-G3: Clear first-line indication with proteinuria
  • CKD G4-G5: Individualized decision; monitor closely for hyperkalemia and AKI
• Dosing: Start low, titrate up to maximally tolerated doses for antiproteinuric effect

Contraindications/cautions:

• Pregnancy (both classes)
• Bilateral renal artery stenosis
• Hyperkalemia (>5.0 mmol/L)
• Acute kidney injury
• Significant volume depletion

Bottom Line

Both ACEi and ARBs provide cardiovascular and renal protection in CKD with hypertension, particularly with proteinuria. ACE inhibitors are generally preferred first-line due to stronger evidence base and lower cost, but ARBs are equally effective alternatives when ACE inhibitors aren't tolerated. The choice should be individualized based on tolerance, cost, and specific patient factors.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical decisions should be made by qualified healthcare professionals based on individual patient needs and current local guidelines.

---

In the management of hypertension (HTN) complicated by Chronic Kidney Disease (CKD), Angiotensin-Converting Enzyme Inhibitors (ACEis) and Angiotensin II Receptor Blockers (ARBs) are considered cornerstone therapies. While they share similar clinical outcomes, their mechanisms, side effect profiles, and specific guideline nuances differ.

Here is a detailed explanation of the key differences, mechanisms, and selection guidelines.

---

1. Mechanism of Action (MOA)

Both drug classes target the Renin-Angiotensin-Aldosterone System (RAAS), but they intervene at different points.

ACE Inhibitors (e.g., Lisinopril, Enalapril, Ramipril)

• Action: Inhibit the Angiotensin-Converting Enzyme (ACE).
• Effect 1: Prevents the conversion of Angiotensin I to Angiotensin II (a potent vasoconstrictor and aldosterone stimulator).
• Effect 2 (Unique to ACEis): Inhibits the breakdown of Bradykinin and Substance P. ACE is the same enzyme responsible for degrading bradykinin.
• Renal Hemodynamics: By reducing Angiotensin II, ACEis preferentially dilate the efferent arteriole of the glomerulus. This lowers intraglomerular pressure, reducing proteinuria and slowing the progression of glomerulosclerosis.

ARBs (e.g., Losartan, Valsartan, Candesartan)

• Action: Selectively block the Angiotensin II Type 1 (AT1) receptor.
• Effect: Prevents Angiotensin II (regardless of how it was formed) from binding to the receptor.
• Bradykinin: ARBs do not affect bradykinin metabolism.
• Renal Hemodynamics: Similar to ACEis, blocking the AT1 receptor leads to efferent arteriole dilation, lowering intraglomerular pressure and reducing proteinuria.

---

2. Key Clinical Differences

While both classes lower blood pressure and provide renoprotection, distinct differences influence tolerability and safety.

Feature	ACE Inhibitors	ARBs
Bradykinin Accumulation	Yes. Leads to specific side effects.	No. Does not inhibit bradykinin breakdown.
Dry Cough	Common (5–20% of patients). Due to bradykinin accumulation in lungs.	Rare. Similar incidence to placebo.
Angioedema	Higher risk (0.1–0.7%). Can be life-threatening.	Lower risk, but not zero. Often used cautiously if ACEi-induced angioedema occurred.
RAAS "Escape"	Angiotensin II levels may rise over time due to non-ACE pathways (e.g., chymase).	Blocks the receptor directly; theoretically more complete AT1 blockade despite circulating Ang II.
Cost/Availability	Generally older, widely available as generics (very low cost).	Generally low cost, though some newer agents may be slightly pricier than ACEis.
Pregnancy	Contraindicated (Fetal toxicity).	Contraindicated (Fetal toxicity).

---

3. Clinical Guidelines for Selection in CKD

Major guidelines (KDIGO, ACC/AHA, ADA) largely view ACEis and ARBs as therapeutically equivalent regarding renal and cardiovascular outcomes. The choice is often driven by tolerability and cost.

A. Indication for Use

• CKD with Albuminuria: Both ACEis and ARBs are first-line therapy for patients with CKD and urinary albumin excretion $\ge$ 300 mg/g (or $\ge$ 30 mg/g in patients with Diabetes).
• CKD without Albuminuria: They are recommended as first-line agents for blood pressure control, though other classes (CCBs, Diuretics) are also acceptable.
• Diabetic Kidney Disease: Strongly recommended if albuminuria is present.

B. Selection Algorithm

1. Initiation: An ACE inhibitor is often prescribed first due to extensive long-term outcome data and lower cost.
2. Intolerance: If the patient develops a persistent dry cough, switch to an ARB.
3. High Risk of Angioedema: In patients with a history of angioedema (unrelated to ACEis) or specific demographic risk factors (e.g., African American ancestry, where ACEi-associated angioedema risk is higher), an ARB may be chosen as the initial agent.
4. Dual Therapy: NEVER combine an ACEi and an ARB.
   • Guideline Consensus: Dual RAAS blockade increases the risk of hyperkalemia and acute kidney injury (AKI) without providing additional cardiovascular or renal benefit.

C. Special Considerations

• Advanced CKD (eGFR < 30): Both classes can be used, but require tighter monitoring. KDIGO suggests continuing RAAS inhibition even in advanced CKD if potassium and hemodynamics allow, as the renoprotective benefit persists.
• Renal Artery Stenosis: Both are contraindicated in bilateral renal artery stenosis (or stenosis of a solitary functioning kidney) due to the risk of precipitating acute renal failure.

---

4. Monitoring and Safety in CKD

Initiating either class in CKD patients requires specific monitoring protocols to ensure safety.

The "Creatinine Bump"

• Expectation: Upon starting an ACEi or ARB, serum creatinine (Scr) may rise. This is hemodynamic (due to efferent arteriole dilation lowering GFR) rather than structural damage.
• Guideline: An increase in Scr of up to 30% within the first 2–4 weeks is acceptable. Do not discontinue the medication unless the rise exceeds 30%, which suggests renal artery stenosis or volume depletion.

Hyperkalemia

• Risk: Both classes reduce aldosterone, decreasing potassium excretion. CKD patients are already prone to hyperkalemia.
• Management: Monitor potassium 1–2 weeks after initiation or dose titration. If K+ > 5.5 mEq/L, consider dietary restriction, diuretics (loop or thiazide), or potassium binders before discontinuing the RAAS inhibitor, as maintaining renoprotection is a priority.

Acute Illness ("Sick Day Rules")

• Patients should be advised to temporarily withhold ACEis/ARBs during episodes of severe dehydration (vomiting, diarrhea, high fever) to prevent pre-renal acute kidney injury.

Summary Recommendation

Feature	Recommendation
Efficacy	Equivalent for BP control and slowing CKD progression.
First Choice	ACE Inhibitor (due to cost/history), unless contraindicated.
Alternative	ARB (if cough develops or prior angioedema).
Critical Warning	Do not use together. Monitor Creatinine and Potassium closely after starting.
Goal	Titrate to maximum tolerated dose to maximize proteinuria reduction, not just BP control.

In conclusion, while the mechanism differs regarding bradykinin handling, the clinical utility in CKD is nearly identical. The selection is primarily a pragmatic decision based on side effect tolerance (cough/angioedema) and the ability to monitor for hyperkalemia and acute changes in kidney function.